Archive for the ‘Shareholders’ Category
Bad News Clouds Two Bio Defense Stocks
Written by Staff and Wire Reports
Tuesday, 08 December 2009 01:28
Key news developments will affect shares of these two companies who help meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons.
The two companies which waited until late after hours on Monday to announce [...]
In: Biothrax, Business, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Management, Shareholders, U.S. Department Of Health And Human Services · Tagged with: BARDA, Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, Federal government of the United States, Fuad El-Hibri, Strategic National Stockpile, United States, United States Department of Health and Human Services
Emergent BioSolutions reacts to BARDA’s Request for Proposal cancellation
by Nick Rees on December 8, 2009
Fuad El-Hibri
The Office of the Biomedical Advanced Research and Development Authority has advised Emergent BioSolutions that while BARDA’s Request for Proposal has been canceled, Emergent is encouraged to submit a proposal for the office’s Broad Agency Announcement.
BARDA canceled the RFP for the procurement for rPA vaccines after [...]
In: Board of directors, Chief executive officer, Clinical trial, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Leadership, Shareholders, U.S. Department Of Health And Human Services, biotechnology · Tagged with: Biotechnology and Pharmaceuticals, Chief executive officer, Emergent BioSolutions, U.S. Food and Drug Administration
Emergent BioSolutions Inc. (EBS) CEO & Chairman, 10% Owner Fuad El-hibri sells 15,000 Shares
CEO & Chairman, 10% Owner of Emergent BioSolutions Inc. (EBS) Fuad El-hibri sells 15,000 shares of EBS on 08/11/2009 at an average price of $16.78 a share.
EMERGENT BIOSULUTIONS INC. is a leading biopharmaceutical company dedicated to one simple mission – to protect life. EBS develops manufactures and commercializes vaccines and therapeutics that assist the body\’s [...]
In: Board of directors, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Infectious disease, Shareholders, U.S. Food and Drug Administration · Tagged with: Anthrax, Anthrax vaccines, Emergent BioSolutions, Health, Infectious disease, Public health, U.S. Food and Drug Administration, Vaccine.
Emergent BioSolutions Inc., Q2 2009 Earnings Call Transcript
Emergent BioSolutions Inc., (EBS)
Q2 2009 Earnings Call
August 6, 2009 5:00 pm ET
Executives
Robert G. Burrows – Vice President, Investor Relations
Fuad El-Hibri – Chairman of the Board, Chief Executive Officer
R. Don Elsey – Chief Financial Officer
Daniel J. Abdun-Nabi – President, Chief Operating Officer
W. James Jackson, Ph.D. – Senior Vice President and Chief Scientific Officer
Analysts
Eric Schmidt [...]
In: Board of directors, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Shareholders, U.S. Food and Drug Administration · Tagged with: Business, Chairman, Chief executive officer, Chief financial officer, Chief operating officer, finance, Investor relations, Vice president